4-溴-5-甲基-1-苯基-1H-吡唑 | 50877-44-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 4-溴-5-甲基-1-苯基-1H-吡唑
• 英文名称: 1-Phenyl-4-brom-5-methylpyrazol
• 英文别名: 4-bromo-5-methyl-1-phenyl-1H-pyrazole；4-Brom-5-methyl-1-phenyl-1H-pyrazol；4-Bromo-5-methyl-1-phenyl-1H-pyrazole；4-bromo-5-methyl-1-phenylpyrazole
• CAS: 50877-44-6
• 化学式: C₁₀H₉BrN₂
• 分子量: 237.099
• InChiKey: GRERYMFLSYSEAY-UHFFFAOYSA-N

物化性质

• 熔点：
  38
• 沸点：
  130 °C(Press: 25 Torr)
• 密度：
  1.44±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2933199090

SDS

Name:	4-Bromo-5-methyl-1-phenyl-1h-pyrazole 97% Material Safety Data Sheet
Synonym:
CAS:	50877-44-6

Section 1 - Chemical Product MSDS Name:4-Bromo-5-methyl-1-phenyl-1h-pyrazole 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
50877-44-6	4-Bromo-5-methyl-1-phenyl-1H-pyrazole	97%	unlisted

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
Causes respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 50877-44-6: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: pale yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 38 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H9BrN2
Molecular Weight: 237.1

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 50877-44-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Bromo-5-methyl-1-phenyl-1H-pyrazole - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 37/39 Wear suitable gloves and eye/face
protection.
WGK (Water Danger/Protection)
CAS# 50877-44-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 50877-44-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 50877-44-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-溴-5-甲基-1-苯基-1H-吡唑 、 碘甲烷 生成 4-bromo-1,3-dimethyl-2-phenyl-pyrazolium; iodide
  参考文献：
  名称：

  Rojahn; Seitz, Justus Liebigs Annalen der Chemie, 1924, vol. 437, p. 303

  摘要：

  DOI：
• 作为产物：
  描述：

  5-甲基-1-苯基-1H-吡唑 在 溴 、 溶剂黄146 作用下， 生成 4-溴-5-甲基-1-苯基-1H-吡唑
  参考文献：
  名称：

  Rojahn; Seitz, Justus Liebigs Annalen der Chemie, 1924, vol. 437, p. 303

  摘要：

  DOI：

文献信息

• [EN] IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS<br/>[FR] COMPOSÉS D'IMIDAZOPYRIDINE ET D'IMIDAZOPYRAZINE UTILISÉS COMME INHIBITEURS DE KINASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2009155388A1

  公开（公告）日：2009-12-23

  A compound of Formula (I) or Formula (II) and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula (I) or Formula (II), and methods of treating conditions associated with the activity of p38 kinase.

  一种由化合物（I）或化合物（II）及其对映体、二对映体和药学上可接受的盐组成的复合物。还公开了含有化合物（I）或化合物（II）的药物组合物，以及治疗与p38激酶活性相关疾病的方法。
• [EN] TRIAZOLOPYRIDINE COMPOUNDS USEFUL AS KINASE INHIBITORS<br/>[FR] COMPOSÉS DE TRIAZOLOPYRIDINE UTILISÉS COMME INHIBITEURS DE KINASE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2009155389A1

  公开（公告）日：2009-12-23

  A compound of Formula (I) and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula (I), and methods of treating conditions associated with the activity of p38 kinase.

  一种由式（I）的化合物及其对映体、二对映体和药用可接受的盐组成的混合物。还公开了含有式（I）化合物的药物组合物，以及治疗与p38激酶活性相关疾病的方法。
• IMIDAZOPYRIDINE AND IMIDAZOPYRAZINE COMPOUNDS USEFUL AS KINASE INHIBITORS
  申请人：Hynes John

  公开号：US20110288085A1

  公开（公告）日：2011-11-24

  A compound of Formula (I) or Formula (II) and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula (I) or Formula (II), and methods of treating conditions associated with the activity of p38 kinase.

  公式（I）或公式（II）的化合物及其对映体、非对映异构体和药学上可接受的盐。还披露了含有公式（I）或公式（II）化合物的药物组合物，以及用于治疗与p38激酶活性相关的疾病的方法。
• Triazolopyridine Compounds Useful As Kinase Inhibitors
  申请人：Hynes John

  公开号：US20110077243A1

  公开（公告）日：2011-03-31

  A compound of Formula (I) and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula (I), and methods of treating conditions associated with the activity of p38 kinase.

  一种化合物，其化学式为（I），包括其对映体、顺反异构体和药学上可接受的盐。还公开了包含化合物（I）的药物组合物以及用于治疗与p38激酶活性相关的疾病的方法。
• Arene C–H Amination with <i>N</i>-Heteroarenes by Catalytic DDQ Photocatalysis
  作者：Kaii Nakayama、Yohei Okada

  DOI：10.1021/acs.joc.3c00293

  日期：2023.5.5

  has an oxidation potential of 2.48 V (vs SCE), was functionalized by pyrazoles, triazoles, tetrazoles, purines, and tert-butoxycarbonyl amine. Arenes underwent amination via a combination of ultraviolet (UV) light and a DDQ photocatalyst without a typical co-oxidant. Although the mechanism remains an open question, DDQH2, which is generated from DDQ after oxidation, is reactivated to DDQ under UV light

  描述了使用催化量的 2,3-二氯-5,6-二氰基-对苯醌 (DDQ) 光催化剂进行的芳烃 C-H 胺化反应。苯的氧化电位为 2.48 V（相对于 SCE），被吡唑、三唑、四唑、嘌呤和叔丁氧基羰基胺官能化。在没有典型助氧化剂的情况下，芳烃通过紫外 (UV) 光和 DDQ 光催化剂的组合进行胺化。虽然该机制仍然是一个悬而未决的问题，但在 DDQ 氧化后产生的 DDQH 2在紫外光照射条件下被重新激活为 DDQ，这可能是在外来 O 2和/或作为末端氧化剂的溶剂的帮助下进行的。这个系统。